title: [Research advances in autoimmune liver diseases in 2016].
abstract: Autoimmune liver diseases are a group of abnormal autoimmune-mediated inflammatory hepatobiliary injuries, mainly including autoimmune hepatitis(AIH), primary biliary cholangitis(PBC), and primary sclerosing cholangitis (PSC). The diagnosis and treatment of autoimmune liver diseases, an important type of non-viral liver disease, have become a prominent issue in hepatology. In 2016, many new advances have been achieved in the clinical and basic research on autoimmune liver diseases, including the phase 3 clinical trial of obeticholic acid, the proposal of UK-PBC risk score, and the research on gut microbiota associated with PSC. This article reviews the research advances in the diagnosis and treatment of autoimmune liver diseases in 2016.
authors.affiliation: Department of Gastroenterology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Institute of Digestive Disease, Shanghai 200001, China.
authors.forename: B
authors.initials: B
authors.lastname: Li
authors.forename: Q X
authors.initials: QX
authors.lastname: Wang
authors.forename: X
authors.initials: X
authors.lastname: Ma
mesh_terms: D001327:Autoimmune Diseases / Q000175:diagnosis* / Q000628:therapy*; D035843:Biomedical Research / Q000639:trends*; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D002761:Cholangitis; D015209:Cholangitis, Sclerosing; D017326:Clinical Trials, Phase III as Topic; D019693:Hepatitis, Autoimmune; D006801:Humans; D008105:Liver Cirrhosis, Biliary; D008107:Liver Diseases
chemical_list: C464660:obeticholic acid; D002635:Chenodeoxycholic Acid
keywords: Hepatitis, autoimmune; Primary biliary cholangitis; Primary sclerosing cholangitis